Lawrence B. Ryan: Final Debarment Order, 12482-12483 [2021-04375]

Download as PDF 12482 Federal Register / Vol. 86, No. 40 / Wednesday, March 3, 2021 / Notices TABLE 2—NEW ENTRIES TO THE LIST OF RECOGNIZED STANDARDS—Continued Title of standard 1 Recognition No. Reference No. and date M. Ophthalmic No new entries at this time. N. Orthopedic 11–368 ................ 11–369 ................ Standard Practice for Finite Element Analysis (FEA) of Metallic Orthopaedic Total Knee Tibial Components. Standard Practice for Inspection of Spinal Implants Undergoing Testing ............... ASTM F3334—19. ASTM F3292—19. O. Physical Medicine No new entries at this time. P. Radiology 12–331 ................ 12–332 ................ 12–333 ................ 12–334 ................ Characterization of Radiofrequency (RF) Coil Heating in Magnetic Resonance Imaging Systems. Magnetic resonance equipment for medical imaging—Part 1: Determination of essential image quality parameters. Guidance on error and warning messages for software used in radiotherapy ....... Radiation therapy machine characterization ............................................................ NEMA Standards Publication MS 14– 2019. IEC 62464–1 Edition 2.0 2018–12. IEC TR 63183 Edition 1.0 2019–12. AAMI RT3:2020. Q. Software/Informatics 13–115 ................ Software and systems engineering—Software testing—Part 1: Concepts and definitions. ISO/IEC/IEEE 29119–1 2013–09–01. First edition R. Sterility 14–549 ................ Standard Test Method for Evaluation of Seal Quality and Integrity Using Airborne Ultrasound. ASTM F3004—13e1. S. Tissue Engineering No new entries at this time. 1 All standard titles in this table conform to the style requirements of the respective organizations. IV. List of Recognized Standards FDA maintains the current list of FDA Recognized Consensus Standards in a searchable database that may be accessed at https:// www.accessdata.fda.gov/scripts/cdrh/ cfdocs/cfStandards/search.cfm. Such standards are those that FDA has recognized by notice published in the Federal Register or that FDA has decided to recognize but for which recognition is pending (because a periodic notice has not yet appeared in the Federal Register). FDA will announce additional modifications and revisions to the list of recognized consensus standards, as needed, in the Federal Register once a year, or more often if necessary. jbell on DSKJLSW7X2PROD with NOTICES V. Recommendation of Standards for Recognition by FDA 17:29 Mar 02, 2021 Jkt 253001 Dated: February 26, 2021. Lauren K. Roth, Acting Principal Associate Commissioner for Policy. [FR Doc. 2021–04376 Filed 3–2–21; 8:45 am] BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2020–N–1638] Any person may recommend consensus standards as candidates for recognition under section 514 of the FD&C Act by submitting such recommendations, with reasons for the recommendation, to CDRHStandardsStaff@fda.hhs.gov. To VerDate Sep<11>2014 be considered, such recommendations should contain, at a minimum, the information listed on FDA’s website, which is specifically available at https:// www.fda.gov/medical-devices/deviceadvice-comprehensive-regulatoryassistance/standards-and-conformityassessment-program#process. Lawrence B. Ryan: Final Debarment Order AGENCY: Food and Drug Administration, HHS. ACTION: PO 00000 Notice. Frm 00073 Fmt 4703 Sfmt 4703 The Food and Drug Administration (FDA or Agency) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) permanently debarring Lawrence B. Ryan from providing services in any capacity to a person that has an approved or pending drug product application. FDA bases this order on a finding that Mr. Ryan was convicted of a felony under Federal law for conduct that relates to the regulation of a drug product under the FD&C Act. Mr. Ryan was given notice of the proposed permanent debarment and an opportunity to request a hearing to show why he should not be debarred. As of October 18, 2020 (30 days after receipt of the notice), Mr. Ryan had not responded. Mr. Ryan’s failure to respond and request a hearing constitutes a waiver of his right to a hearing concerning this action. DATES: This order is applicable March 3, 2021. ADDRESSES: Submit applications for termination of debarment to the Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers SUMMARY: E:\FR\FM\03MRN1.SGM 03MRN1 Federal Register / Vol. 86, No. 40 / Wednesday, March 3, 2021 / Notices jbell on DSKJLSW7X2PROD with NOTICES Lane, Rm. 1061, Rockville, MD 20852, 240–402–7500, or at https:// www.regulations.gov. FOR FURTHER INFORMATION CONTACT: Jaime Espinosa, (ELEM–4029) Division of Enforcement, Office of Strategic Planning and Operational Policy, Office of Regulatory Affairs, Food and Drug Administration, 12420 Parklawn Dr., Rockville, MD 20857, 240–402–8743, or at debarments@fda.hhs.gov. SUPPLEMENTARY INFORMATION: I. Background Section 306(a)(2)(B) of the FD&C Act (21 U.S.C. 335a(a)(2)(B)) requires debarment of an individual from providing services in any capacity to a person that has an approved or pending drug product application if FDA finds that the individual has been convicted of a felony under Federal law for conduct relating to the regulation of any drug product under the FD&C Act. On June 18, 2020, Mr. Ryan was convicted as defined in section 306(l)(1) of the FD&C Act when judgment was entered against him in the U.S. District Court for the Eastern District of Virginia, Norfolk Division, after his plea of guilty to one count of conspiracy to defraud the United States in violation of 18 U.S.C. 371. The factual basis for this conviction is as follows: As contained in the Statement of Facts in Mr. Ryan’s case, filed on January 8, 2020, from October 2007, and continuing through September 2010, Mr. Ryan, a physician, authorized drug orders for RX Limited (also known as RX Partners), an internet pharmacy organization that facilitated the unlawful distribution of prescription drugs to consumers throughout the United States. RX Limited had a business model whereby it allowed consumers to fill out a brief medical questionnaire, select the type of drugs the consumer desired, the desired drug strength, and the desired drug quantity and pay by credit card. RX Limited then forwarded the order to a participating physician for ‘‘approval.’’ The drugs sold by RX Limited were dispensed without a valid prescription because there was no valid doctor-patient relationship established between the authorizing physicians and the customers. Customers had no face-toface contact with the participating physician and were not subject to any mental or physical examinations. The physicians authorizing the orders for prescription drugs sold by RX Limited did not take patient histories or perform any diagnostic or laboratory testing, did not check the accuracy of the information customers provided VerDate Sep<11>2014 17:29 Mar 02, 2021 Jkt 253001 (including their identities, ages, and qualifying medical conditions), and did not monitor, or provide any means to monitor, medication response. After the participating physician authorized the prescription, RX Limited sent the order to a fulfillment pharmacy, which fulfilled the order and mailed the drugs to the customer. As a participating physician, Mr. Ryan authorized more than 158,000 drug orders for well over 10 individual RX Limited customers. Prescription drugs distributed pursuant to these orders included, FIORICET (and its generic equivalents), Carisoprodol (SOMA), Tramadol (ULTRAM), VIAGRA, CIALIS, and XENICAL. RX Limited paid Mr. Ryan $2.00 per drug order he authorized. From October 2007 through September 2010, RX Limited paid Mr. Ryan at least $316,153 for the orders he authorized. As a result of this conviction, FDA sent Mr. Ryan by certified mail on September 11, 2020, a notice proposing to permanently debar him from providing services in any capacity to a person that has an approved or pending drug product application. The proposal was based on a finding, under section 306(a)(2)(B) of the FD&C Act, that Mr. Ryan was convicted of a felony under Federal law for conduct relating to the regulation of a drug product under the FD&C Act. The proposal also offered Mr. Ryan an opportunity to request a hearing, providing him 30 days from the date of receipt of the letter in which to file the request, and advised him that failure to request a hearing constituted an election not to use the opportunity for a hearing and a waiver of any contentions concerning this action. Mr. Ryan received the proposal on September 18, 2020. Mr. Ryan did not request a hearing within the timeframe prescribed by regulation and has, therefore, waived his opportunity for a hearing and any contentions concerning his debarment (21 CFR part 12). II. Findings and Order Therefore, the Assistant Commissioner, Office of Human and Animal Food Operations, under section 306(a)(2)(B) of the FD&C Act, under authority delegated to the Assistant Commissioner, finds that Mr. Ryan, has been convicted of a felony under Federal law for conduct otherwise relating to the regulation of a drug product under the FD&C Act. As a result of the foregoing finding, Mr. Ryan, is permanently debarred from providing services in any capacity to a person with an approved or pending drug product application, effective (see DATES) (see sections 306(a)(2)(B) and PO 00000 Frm 00074 Fmt 4703 Sfmt 4703 12483 (c)(2)(A)(ii) of the FD&C Act). Any person with an approved or pending drug product application who knowingly employs or retains as a consultant or contractor, or otherwise uses the services of, Mr. Ryan, in any capacity during his debarment, will be subject to civil money penalties (section 307(a)(6) of the FD&C Act (21 U.S.C. 335b(a)(6))). If Mr. Ryan provides services in any capacity to a person with an approved or pending drug product application during his period of debarment, he will be subject to civil money penalties (section 307(a)(7) of the FD&C Act). In addition, FDA will not accept or review any abbreviated new drug application from Mr. Ryan during his period of debarment, other than in connection with an audit under section 306 of the FD&C Act (section 306(c)(1)(B)). Note that, for purposes of section 306 of the FD&C Act, a ‘‘drug product’’ is defined as a drug subject to regulation under section 505, 512, or 802 of the FD&C Act (21 U.S.C. 355, 360b, or 382) or under section 351 of the Public Health Service Act (42 U.S.C. 262) (see section 201(dd) of the FD&C Act (21 U.S.C. 321(dd))). Any application by Mr. Ryan for special termination of debarment under section 306(d)(4) of the FD&C Act should be identified with Docket No. FDA–2020–N–1638 and sent to the Dockets Management Staff (see ADDRESSES). The public availability of information in these submissions is governed by 21 CFR 10.20. Publicly available submissions will be placed in the docket and will be viewable at https://www.regulations.gov or at the Dockets Management Staff (see ADDRESSES) between 9 a.m. and 4 p.m., Monday through Friday, 240–402–7500. Dated: February 25, 2021. Lauren K. Roth, Acting Principal Associate Commissioner for Policy. [FR Doc. 2021–04375 Filed 3–2–21; 8:45 am] BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2021–N–0008] Circulatory System Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice. The Food and Drug Administration (FDA) announces a SUMMARY: E:\FR\FM\03MRN1.SGM 03MRN1

Agencies

[Federal Register Volume 86, Number 40 (Wednesday, March 3, 2021)]
[Notices]
[Pages 12482-12483]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-04375]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2020-N-1638]


Lawrence B. Ryan: Final Debarment Order

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) is issuing an 
order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) 
permanently debarring Lawrence B. Ryan from providing services in any 
capacity to a person that has an approved or pending drug product 
application. FDA bases this order on a finding that Mr. Ryan was 
convicted of a felony under Federal law for conduct that relates to the 
regulation of a drug product under the FD&C Act. Mr. Ryan was given 
notice of the proposed permanent debarment and an opportunity to 
request a hearing to show why he should not be debarred. As of October 
18, 2020 (30 days after receipt of the notice), Mr. Ryan had not 
responded. Mr. Ryan's failure to respond and request a hearing 
constitutes a waiver of his right to a hearing concerning this action.

DATES: This order is applicable March 3, 2021.

ADDRESSES: Submit applications for termination of debarment to the 
Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 
Fishers

[[Page 12483]]

Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500, or at https://www.regulations.gov.

FOR FURTHER INFORMATION CONTACT: Jaime Espinosa, (ELEM-4029) Division 
of Enforcement, Office of Strategic Planning and Operational Policy, 
Office of Regulatory Affairs, Food and Drug Administration, 12420 
Parklawn Dr., Rockville, MD 20857, 240-402-8743, or at 
[email protected].

SUPPLEMENTARY INFORMATION: 

I. Background

    Section 306(a)(2)(B) of the FD&C Act (21 U.S.C. 335a(a)(2)(B)) 
requires debarment of an individual from providing services in any 
capacity to a person that has an approved or pending drug product 
application if FDA finds that the individual has been convicted of a 
felony under Federal law for conduct relating to the regulation of any 
drug product under the FD&C Act. On June 18, 2020, Mr. Ryan was 
convicted as defined in section 306(l)(1) of the FD&C Act when judgment 
was entered against him in the U.S. District Court for the Eastern 
District of Virginia, Norfolk Division, after his plea of guilty to one 
count of conspiracy to defraud the United States in violation of 18 
U.S.C. 371.
    The factual basis for this conviction is as follows: As contained 
in the Statement of Facts in Mr. Ryan's case, filed on January 8, 2020, 
from October 2007, and continuing through September 2010, Mr. Ryan, a 
physician, authorized drug orders for RX Limited (also known as RX 
Partners), an internet pharmacy organization that facilitated the 
unlawful distribution of prescription drugs to consumers throughout the 
United States. RX Limited had a business model whereby it allowed 
consumers to fill out a brief medical questionnaire, select the type of 
drugs the consumer desired, the desired drug strength, and the desired 
drug quantity and pay by credit card. RX Limited then forwarded the 
order to a participating physician for ``approval.'' The drugs sold by 
RX Limited were dispensed without a valid prescription because there 
was no valid doctor-patient relationship established between the 
authorizing physicians and the customers. Customers had no face-to-face 
contact with the participating physician and were not subject to any 
mental or physical examinations.
    The physicians authorizing the orders for prescription drugs sold 
by RX Limited did not take patient histories or perform any diagnostic 
or laboratory testing, did not check the accuracy of the information 
customers provided (including their identities, ages, and qualifying 
medical conditions), and did not monitor, or provide any means to 
monitor, medication response. After the participating physician 
authorized the prescription, RX Limited sent the order to a fulfillment 
pharmacy, which fulfilled the order and mailed the drugs to the 
customer.
    As a participating physician, Mr. Ryan authorized more than 158,000 
drug orders for well over 10 individual RX Limited customers. 
Prescription drugs distributed pursuant to these orders included, 
FIORICET (and its generic equivalents), Carisoprodol (SOMA), Tramadol 
(ULTRAM), VIAGRA, CIALIS, and XENICAL. RX Limited paid Mr. Ryan $2.00 
per drug order he authorized. From October 2007 through September 2010, 
RX Limited paid Mr. Ryan at least $316,153 for the orders he 
authorized.
    As a result of this conviction, FDA sent Mr. Ryan by certified mail 
on September 11, 2020, a notice proposing to permanently debar him from 
providing services in any capacity to a person that has an approved or 
pending drug product application. The proposal was based on a finding, 
under section 306(a)(2)(B) of the FD&C Act, that Mr. Ryan was convicted 
of a felony under Federal law for conduct relating to the regulation of 
a drug product under the FD&C Act. The proposal also offered Mr. Ryan 
an opportunity to request a hearing, providing him 30 days from the 
date of receipt of the letter in which to file the request, and advised 
him that failure to request a hearing constituted an election not to 
use the opportunity for a hearing and a waiver of any contentions 
concerning this action. Mr. Ryan received the proposal on September 18, 
2020. Mr. Ryan did not request a hearing within the timeframe 
prescribed by regulation and has, therefore, waived his opportunity for 
a hearing and any contentions concerning his debarment (21 CFR part 
12).

II. Findings and Order

    Therefore, the Assistant Commissioner, Office of Human and Animal 
Food Operations, under section 306(a)(2)(B) of the FD&C Act, under 
authority delegated to the Assistant Commissioner, finds that Mr. Ryan, 
has been convicted of a felony under Federal law for conduct otherwise 
relating to the regulation of a drug product under the FD&C Act.
    As a result of the foregoing finding, Mr. Ryan, is permanently 
debarred from providing services in any capacity to a person with an 
approved or pending drug product application, effective (see DATES) 
(see sections 306(a)(2)(B) and (c)(2)(A)(ii) of the FD&C Act). Any 
person with an approved or pending drug product application who 
knowingly employs or retains as a consultant or contractor, or 
otherwise uses the services of, Mr. Ryan, in any capacity during his 
debarment, will be subject to civil money penalties (section 307(a)(6) 
of the FD&C Act (21 U.S.C. 335b(a)(6))). If Mr. Ryan provides services 
in any capacity to a person with an approved or pending drug product 
application during his period of debarment, he will be subject to civil 
money penalties (section 307(a)(7) of the FD&C Act). In addition, FDA 
will not accept or review any abbreviated new drug application from Mr. 
Ryan during his period of debarment, other than in connection with an 
audit under section 306 of the FD&C Act (section 306(c)(1)(B)). Note 
that, for purposes of section 306 of the FD&C Act, a ``drug product'' 
is defined as a drug subject to regulation under section 505, 512, or 
802 of the FD&C Act (21 U.S.C. 355, 360b, or 382) or under section 351 
of the Public Health Service Act (42 U.S.C. 262) (see section 201(dd) 
of the FD&C Act (21 U.S.C. 321(dd))).
    Any application by Mr. Ryan for special termination of debarment 
under section 306(d)(4) of the FD&C Act should be identified with 
Docket No. FDA-2020-N-1638 and sent to the Dockets Management Staff 
(see ADDRESSES). The public availability of information in these 
submissions is governed by 21 CFR 10.20.
    Publicly available submissions will be placed in the docket and 
will be viewable at https://www.regulations.gov or at the Dockets 
Management Staff (see ADDRESSES) between 9 a.m. and 4 p.m., Monday 
through Friday, 240-402-7500.

    Dated: February 25, 2021.
Lauren K. Roth,
Acting Principal Associate Commissioner for Policy.
[FR Doc. 2021-04375 Filed 3-2-21; 8:45 am]
BILLING CODE 4164-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.